Publications by authors named "Jackie Droste"
Article Synopsis
- Iron overload from red blood cell transfusions can lead to serious health issues in lower-risk myelodysplastic syndrome (MDS) patients, with iron chelation therapy (ICT) potentially improving survival rates.
- This study analyzed data from the European MDS registry to compare patients who received ICT with those who did not, using various statistical models to assess overall survival.
- The results indicated that patients receiving ICT had significantly better survival rates and about 39% showed improvement in blood cell production, suggesting ICT could benefit transfused MDS patients.
In myelodysplastic syndromes (MDS), health-related quality of life (HRQoL) represents a relevant patient-reported outcome, which is essential in individualized therapy planning. Prospective data on HRQoL in lower-risk MDS remain rare. We assessed HRQOL by EQ-5D questionnaire at initial diagnosis in 1690 consecutive IPSS-Low/Int-1 MDS patients from the European LeukemiaNet Registry.
View Article and Find Full Text PDFRed blood cell transfusions remain one of the cornerstones in supportive care of lower-risk patients with myelodysplastic syndromes. We hypothesized that patients develop oxidant-mediated tissue injury through the formation of toxic iron species, caused either by red blood cell transfusions or by ineffective erythropoiesis. We analyzed serum samples from 100 lower-risk patients with myelodysplastic syndromes at six-month intervals for transferrin saturation, hepcidin-25, growth differentiation factor 15, soluble transferrin receptor, non-transferrin bound iron and labile plasma iron in order to evaluate temporal changes in iron metabolism and the presence of potentially toxic iron species and their impact on survival.
View Article and Find Full Text PDFThe European LeukemiaNet MDS (EUMDS) registry is collecting data of myelodysplastic syndrome (MDS) patients belonging to the IPSS low or intermediate-1 category, newly diagnosed by local cytologists. The diagnosis of MDS can be challenging, and some data report inter-observer variability with regard to the assessment of the MDS subtype. In order to ensure that correct diagnoses were made by the participating centres, blood and bone marrow slides of 10% of the first 1000 patients were reviewed by an 11-person panel of cytomorphologists.
View Article and Find Full Text PDFArticle Synopsis
- The study examined 1000 lower-risk myelodysplastic syndrome (MDS) patients from the European LeukaemiaNet MDS registry, validating the revised International Prognostic Scoring System (IPSS-R) for better prognostic assessment.
- Key findings included that lower quality of life scores and high co-morbidity indices were linked to poorer survival outcomes, confirming previous prognostic factors.
- The IPSS-R outperformed the original IPSS in predicting disease progression and survival, with 70% of patients receiving specific treatments and supportive care shortly after diagnosis.